AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Why Biopharma Breakthroughs Aren't Moving The Market
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
Accelerate Cell Expansion And Sustain Viability With A Serum-Free Medium
Discover how Corning's Insect Cell serum-free medium outperforms other commercial media in yield, doubling time, and cell viability by diving into the study results.
-
3D Cell Culture Reveals Undetectable Drug Efficacy In Traditional Systems
Drug discovery now targets cancer stem cells (CSCs) to achieve long-term tumor eradication, which moves beyond traditional chemotherapeutics. Discover an advanced screening platform that better predicts CSC inhibitor efficacy.
-
Laminar And Turbulent Mixing Techniques For LNP Formulations Scale Up
Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.
-
Best Practices For Oncolytic Virus Design, Development, Manufacturing
Oncolytic viruses have the potential to revolutionize standard cancer treatment, but their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up.
-
A Digital Solution Embeds Quality Into Cellular Therapeutics Production
Discover how Dendreon cut review and release time by nearly 50% while maintaining a 99% right-first-time rate, which boosts collaboration, visibility, and operational efficiency across teams.
-
Simplify CAPA In 7 Steps
Discover how to streamline corrective action/preventive action (CAPA) management in regulatory environments in 7 steps.
-
Large-Scale Exosome Production Stirred-Tank Bioreactors
Discover how engineered exosomes, displaying tumor-homing peptides, offer a promising tool for targeted cytotoxic drug delivery, produced efficiently with a bioreactor for critical research.
-
Standardize Flow Cytometry Data With Easy Assay Transfer Across Sites
Gain insight into how a global pharmaceutical company successfully transferred their cell therapy assays across international locations.
-
Cell Culture Media Filtration: Evaluating Cell Culture Performance
Cell culture performance remained consistent across PES and PVDF filters, even under worst-case filtration conditions. Discover a practical framework for evaluating membrane impact on CHO cell growth.
NEWSLETTER ARCHIVE
- 02.27.26 -- Optimize Your Cell And Gene Therapy Manufacturing Workflows
- 02.27.26 -- Active Versus Passive Shipping Solutions For Clinical Shipments
- 02.26.26 -- January 2026 — CDMO Opportunities And Threats Report
- 02.26.26 -- Unlocking Reliability And Speed In CGT
- 02.25.26 -- Securing And Strengthening Workflows From Design To Delivery
- Powering AI And Synthetic Biology In Therapy Design
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections